Accession Number : AD1040554


Title :   Annual Surveillance Summary: Vancomycin-Resistant Enterococci (VRE) Infections in the Military Health System (MHS), 2016


Descriptive Note : Technical Report,01 Jan 2016,31 Dec 2016


Corporate Author : NAVY AND MARINE CORPS PUBLIC HEALTH CENTER PORTSMOUTH VA PORTSMOUTH


Personal Author(s) : Rossi,Kristen ; Chukwuma,Uzo


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1040554.pdf


Report Date : 01 Jun 2017


Pagination or Media Count : 21


Abstract : The EpiData Center Department (EDC) conducts routine surveillance of vancomycin-resistant enterococci (VRE) incidence and prevalence among all beneficiaries seeking care within the Military Health System (MHS). This report describes demographics, clinical characteristics, prescription practices, and antibiotic resistance patterns observed for VRE in calendar year (CY) 2016. Multiple data sources were linked to assess descriptive and clinical factors related to VRE. Health Level 7 (HL7)-formatted Composite Health Care System (CHCS) microbiology data identified Enterococcus species infections with vancomycin resistance. These infections were matched to HL7-formatted CHCS pharmacy data to assess prescription practices, the Standard Inpatient Data Record (SIDR) to determine healthcare-associated exposures, Defense Manpower Data Center (DMDC) rosters to determine burden among Department of Defense (DOD) active duty (AD) service members, and the DMDC Contingency Tracking System (CTS) to determine Department of the Navy (DON) deployment-related infections. In 2016, VRE infection rates declined among MHS beneficiaries to 1.38 per 100,000 persons per year, following a three-year incline from 2013-2015. The United States (US) West and South regions had the highest rates, and healthcare-associated (HA) cases comprised the largest proportion of all infections identified (87 ). While the majority of all prevalent infections were classified as hospital-onset (HO) (45 ), a substantial proportion was also identified as community-onset (CO) (31 ). Treatment for VRE infections among DOD beneficiaries primarily included daptomycin and linezolid, which remained effective throughout 2016. These findings warrant continued surveillance to understand the evolving impact of VRE within the MHS.


Descriptors :   microbiology , surveillance , military medicine , DRUG RESISTANCE , demography , patterns , Epidemiology , antiinfective agents


Subject Categories : Microbiology
      Pharmacology
      Military Forces and Organizations


Distribution Statement : APPROVED FOR PUBLIC RELEASE